Chinese Oncology-Focused Innovative Drugs Developer Haihe Biopharma Nets $146M

Login to View

Haihe Biopharma Co., a Chinese pharmaceutical company specialized in innovative oncology drugs, has secured a US$146.6 million new round of investment led by China-focused private equity firm Huagai Capital, said Haihe Biopharma in a statement released on Monday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 3 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription for $359

Enjoy comprehensive and exclusive data you can't find elsewhere!

Subscribe for $359

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in